NCT00674063View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG

alefacept

IV

Trial Locations (17)

11790

Stony Brook

23507

Norfolk

37072

Goodlettsville

37215

Nashville

55432

Fridley

68144

Omaha

71913

Hot Springs

97035

Lake Oswego

97210

Portland

08520

East Windsor

02919

Johnston

E1C 8X3

Moncton

L8N 1V6

Hamilton

N6K 1L6

London

N2J 1C4

Waterloo

N8W 5L7

Windsor

H3H 1V4

Montreal

Sponsors

Lead Sponsor

Astellas Pharma Inc

Collaborators (1)

All Listed Sponsors

collaborator

Biogen

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY